AstraZeneca PLC (LSE:AZN, NYSE:AZN) offers a compelling risk-reward opportunity ahead of a busy slate of late-stage trial readouts in 2027, according to JPMorgan. The broker said upcoming Phase III ...

AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to ...

By Bhanvi Satija MADRID, Oct 25 (Reuters) - AstraZeneca's experimental drug sone-ve helped patients with advanced stomach ...

Astrazeneca (NYSE:AZN) highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support ...

A 53% cut in death risk versus chemotherapy is the kind of late-stage result that resets an oncology franchise, and it lands ...

AstraZeneca ( AZN) said its experimental stomach cancer treatment doubled survival time in a late-stage clinical trial, ...

AstraZeneca heads into its October 30 earnings call with oncology surging and its cardiology franchise under pressure, ...

AstraZeneca agrees a $40m upfront deal with insitro to use AI in drug discovery for MASH and cardiomyopathies. Read more.

Oct 20 () - Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved ...

AstraZeneca has seen major momentum in oncology in recent years. It got a big showcase at Europe's top cancer conference.

Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.